Investor Update
Logotype for Suzano S.A

Suzano (SUZB3) Investor Update summary

Event summary combining transcript, slides, and related documents.

Logotype for Suzano S.A

Investor Update summary

12 Nov, 2025

Strategic rationale and transaction structure

  • Suzano will control a new joint venture with Kimberly-Clark, holding 51% ownership and appointing the majority of the board, CEO, and CFO, with a call option to acquire the remaining 49% after three years at a pre-agreed multiple.

  • The JV covers 14 countries, 22 facilities, and will be headquartered in the Netherlands, operating independently from Suzano's core business.

  • The partnership combines Suzano's industrial expertise with Kimberly-Clark's commercial and branding strengths, aiming to accelerate the fiber-to-fiber strategy in the global tissue market.

  • The JV will have access to global and local premium brands, including a 30-year royalty-free license for Kleenex, Scott, Andrex, and 40 local brands.

  • The deal is expected to close by mid-2026, pending regulatory approvals, with signing and payment expected by June 4, 2025, and integration planning underway.

Financial impact and synergies

  • The transaction values the business at $3.4 billion enterprise value, with a potential $1 billion in net debt at closing, reducing Suzano's equity disbursement to $1.2 billion; acquisition value is set at USD 1.734 billion.

  • Expected annual revenues are $3.3 billion, EBITDA $500 million, and free cash flow generation around $300 million.

  • Estimated operational synergies of $175 million per year to be fully realized within three years, mainly from procurement, industrial efficiencies, logistics, and G&A, with no major CapEx required.

  • The JV is expected to deliver an IRR above 15%, with efficiency gains modeled conservatively compared to prior Brazilian operations; expected unleveraged IRR is 15.5% in US dollar nominal terms.

  • The transaction is designed to have limited impact on leverage, maintain Suzano’s investment-grade status, and reduce cash flow volatility.

Business overview and operational footprint

  • The joint venture will have 1.0 million tons of tissue capacity, 22 mills in 14 countries, and sales in over 70 countries.

  • The business will operate in two segments: Family Care and Professional.

  • Revenue distribution is diversified across EMEA, UK, Latin America, Asia, and Oceania.

  • The JV will operate with an average annual sustained CapEx of $100 million.

  • No changes are expected in Suzano’s pulp inventory management as the JV will operate independently.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more